• Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise

Log in

Start free trial
G2 Intelligence
  • Reports
    • Lab Industry Advisor
      • Essentials Reports
      • Premium Reports
      • Elite Reports
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Articles
    • Lab Industry Advisor
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Webinars
  • Store
  • Reports
    • Lab Industry Advisor
      • Essentials Reports
      • Premium Reports
      • Elite Reports
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Articles
    • Lab Industry Advisor
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Webinars
  • Store
Special Report: Preparing for Stage 1 of the FDA’s LDTs Final Rule

Special Report: Preparing for Stage 1 of the FDA’s LDTs Final Rule

by Rachel Muenz | Nov 21, 2024 | Compliance Perspectives-lca, FDA-lca, Lab Industry Advisor, Premium

Considerations for addressing compliance with Stage 1 of the FDA’s lab-developed tests final rule

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
How the LDT Final Rule’s Exemptions Apply to Oncology Labs

How the LDT Final Rule’s Exemptions Apply to Oncology Labs

by Scott Wallask | Nov 7, 2024 | Compliance Perspectives-lca, Compliance-lca, Essential, FDA-lca, Lab Industry Advisor

Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
FDA Watch: FDA Approves Enhanced Cologuard Cancer Test

FDA Watch: FDA Approves Enhanced Cologuard Cancer Test

by Ron Shinkman | Nov 1, 2024 | CDC-nir, Essential, FDA-lca, Lab Industry Advisor

Test maker Exact Sciences says it expects Cologuard Plus to cut false positives by more than 30 percent

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
What Labs Need to Know About Reporting Adverse Events to the FDA

What Labs Need to Know About Reporting Adverse Events to the FDA

by Tara Cepull, MA | Nov 1, 2024 | Compliance Perspectives-lca, Compliance-lca, Essential, FDA-lca, Lab Industry Advisor

Understanding the process and implementing proper procedures is the key to ensuring compliance when reporting such events

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Esophageal Pre-Cancer Testing Gaining Greater Traction

Esophageal Pre-Cancer Testing Gaining Greater Traction

by Ron Shinkman | Oct 29, 2024 | Clinical Diagnostics Insider, FDA-dtet

How three companies are addressing screening challenges with tests that help improve chances of early detection

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
« Older Entries
Next Entries »

Log In

Join Now | Lost Password?
  • Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
Copyright © 2025 G2Intelligence.com